Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore

References

• Dankó D, Blay JY, Garrison LP. Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology. Health Policy. 2019;123(12):1230–1236.
   PubMed Web of Science ®Google Scholar
• Davis S NICE DSU Report. Assessing technologies that are not cost-effective at zero price. 2014.
   Google Scholar
• Phua LC, Lee SC, Ng K, et al. Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer. BMC Health Serv Res. 2020;20(1):581.
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortés J, Kim SB, et al., Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012; 366(2): 109–119.
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim SB, et al., Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015; 372(8): 724–734.
   PubMed Web of Science ®Google Scholar
• Swain SM, Miles D, Kim SB, et al., Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(4): 519–530.
   PubMed Web of Science ®Google Scholar
• Pearce F, Lin L, Teo E, et al. Health technology assessment and its use in drug policies: Singapore. Value Health Reg Issues. 2019;18:176–183.
   PubMedGoogle Scholar
• Drug evaluation methods and process guide v2.0 agency for care effectiveness. Singapore: Ministry of Health; [2020Aug12]. Available from: https://www.ace-hta.gov.sg.
   Google Scholar
• Abiraterone for treating metastatic prostate cancer. Technology guidance. agency for care effectiveness. Singapore: Ministry of Health; [2020Oct1]. Available from https://www.ace-hta.gov.sg.
   Google Scholar
• Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia. Technology guidance. agency for care effectiveness. Singapore: Ministry of Health; [2020Sept1]. Available from https://www.ace-hta.gov.sg.
   Google Scholar
• Aziz MIA, Tan LE, Tan WHG, et al. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer. J Med Econ. 2020;23(9):952–960.
   PubMed Web of Science ®Google Scholar
• Tan PT, Aziz MIA, Pearce F, et al. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective. BMC Cancer. 2018;18(1):352.
   PubMedGoogle Scholar
• Eng LG, Dawood S, Sopik V, et al. Ten-year survival in women with primary stage IV breast cancer. Breast Cancer Res Treat. 2016;160(1):145–152.
   PubMed Web of Science ®Google Scholar
• Rohatgi A WebPlotDigitizer Version 4.2 [cited 2020 Oct 19] [ Available from: http://arohatgi.ifo.
   Google Scholar
• Guyot P, Ades A, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9.
   PubMed Web of Science ®Google Scholar
• Chow GC. Tests of equality between sets of coefficients in two linear regressions. Econometrica. 1960;28(3):591–605.
   Web of Science ®Google Scholar
• Department of Statistics, Complete life tables for Singapore Resident Population, 2016–2017. 2018 [accessed on 2018 Nov 30]. Available from: https://www.singstat.gov.sg/publications/population/-/media/Files/publications/population/lifetable16–17
   Google Scholar
• Galve-Calvo E, González-Haba E, Gostkorzewicz J, et al. Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain. Clinicoecon Outcomes Res. 2018;10:773–790.
   PubMed Web of Science ®Google Scholar
• Garrison LP, Babigumira J, Tournier C, et al. Cost-effectiveness analysis of pertuzumab with trastuzumab and chemotherapy compared to trastuzumab and chemotherapy in the adjuvant treatment of HER2-positive breast cancer in the United States. Value Health. 2019;22(4):408–415.
   PubMed Web of Science ®Google Scholar
• Sabale U, Ekman M, Thunström D, et al. Economic evaluation of fulvestrant 500 mg compared to generic aromatase inhibitors in patients with advanced breast cancer in Sweden. Pharmacoecon Open. 2017;1(4):279–290.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683–690.
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791.
   PubMed Web of Science ®Google Scholar
• Drug evaluation methods and process guide. Agency for care effectiveness, Singapore. 2019. [Version 2.0 updated December 2019] [accessed on 2020 Oct 19]. Available from: www.ace-hta.gov.sg/our-process-and-methods.html#health-technology.
   Google Scholar
• Cholesky Decomposition: International Encyclopedia of the Social Sciences; [cited 2020 May 29]. Available from: www.encyclopedia.com/social-sciences/applied-and-social-sciences-magazines/cholesky-decomposition.
   Google Scholar
• Durkee BY, Qian Y, Pollom EL, et al., Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2016; 34(9): 902–909.
   PubMed Web of Science ®Google Scholar
• Diaby V, Adunlin G, Ali AA, et al., Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat. 2016; 160(1): 187–196.
   PubMed Web of Science ®Google Scholar
• Diaby V, Ali AA, Williams KJ, et al., Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. Breast Cancer Res Treat. 2017; 166(3): 951–963.
   PubMed Web of Science ®Google Scholar
• Diaby V, Alqhtani H, van Boemmel-wegmann S, et al. A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. Breast. 2020;49:141–148.
   PubMed Web of Science ®Google Scholar
• Woods B, Sideris E, Palmer S NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review.2017 cited 2020 Sept 20]. Available from: www.nicedsu.org.uk/wp-content/uploads/2017/06/Partitioned-Survival-Analysis-final-report.pdf.
   Google Scholar
• Cranmer H, Shields GE, Bullement A. A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology. J Med Econ. 2020;23(10):1176–1185.
   PubMed Web of Science ®Google Scholar
• Health sciences authority- health products regulation group. Guidance on Therapeutic Product Registration in Singapore - Guidance on registration of biosimilar products. 2016.
   Google Scholar
• Pimentel F, Toledo J, Goncalves J, et al.editors. Comparative evaluation of a trastuzumab biosimilar or originator trastuzumab in association with pertuzumab: binding and biological activities in cell culture-based assays. PS-05-08. San Antonio Breast Cancer Symposium 2019.San Antonio, Texas, USA.
   Google Scholar
• Claessens AKM, Ramaekers BLT, Lobbezoo DJA, et al. Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry. Qual Life Res. 2020;29(12):3363–3374.
   PubMed Web of Science ®Google Scholar